InnoCan Pharma Valuation

Is INNO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INNO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate INNO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate INNO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INNO?

Key metric: As INNO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for INNO. This is calculated by dividing INNO's market cap by their current revenue.
What is INNO's PS Ratio?
PS Ratio	1.5x
Sales	US$28.93m
Market Cap	US$43.11m

INNO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	-33.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does INNO's PS Ratio compare to its peers?

The above table shows the PS ratio for INNO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.1x
MSET Mindset Pharma	9.7x	43.8%	CA$75.0m
EPIC 1CM	0.6x	n/a	CA$29.4m
YOUR YourWay Cannabis Brands	0.3x	n/a	CA$23.2m
GWAY Greenway Greenhouse Cannabis	10x	n/a	CA$64.4m
INNO InnoCan Pharma	1.5x	n/a	CA$60.3m

Price-To-Sales vs Peers: INNO is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (5.3x).

Price to Sales Ratio vs Industry

How does INNO's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

25 Companies	Price / Sales	Estimated Growth	Market Cap
AYR.A Ayr Wellness	0.2x	2.6%	US$79.90m
TIUM.U Cansortium	0.2x	n/a	US$25.68m
ACRG.A.U Acreage Holdings	0.09x	n/a	US$20.65m
MRV Nuvo Pharmaceuticals	0.2x	n/a	US$11.21m

25 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: INNO is expensive based on its Price-To-Sales Ratio (1.5x) compared to the Canadian Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is INNO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INNO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate INNO's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Verano Holdings

CA$722.2m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.02

-14.8%

-65.2%

Fennec Pharmaceuticals

US$145.9m

Operates as a biopharmaceutical company in the United States.

FRX

US$7.35

30.1%

-38.9%

Medexus Pharmaceuticals

CA$60.4m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.45

15.6%

61.2%